Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V. Giraud N, et al. Among authors: mirabel x. Cancers (Basel). 2021 Jan 7;13(2):193. doi: 10.3390/cancers13020193. Cancers (Basel). 2021. PMID: 33430396 Free PMC article.
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03).
Tournier-Rangeard L, Mercier M, Peiffert D, Gerard JP, Romestaing P, Lemanski C, Mirabel X, Pommier P, Denis B. Tournier-Rangeard L, et al. Among authors: mirabel x. Radiother Oncol. 2008 Jun;87(3):391-7. doi: 10.1016/j.radonc.2007.12.004. Epub 2008 Jan 11. Radiother Oncol. 2008. PMID: 18191265 Clinical Trial.
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.
Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J, Mahé M, Bécouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne L, Gourgou-Bourgade S, Juzyna B, Conroy T, Gérard J. Azria D, et al. Among authors: mirabel x. Ann Oncol. 2017 Oct 1;28(10):2436-2442. doi: 10.1093/annonc/mdx351. Ann Oncol. 2017. PMID: 28961836 Free article. Clinical Trial.
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03).
Faivre JC, Peiffert D, Vendrely V, Lemanski C, Hannoun-Levi JM, Mirabel X, Stanbury T, Salleron J, Guillemin F. Faivre JC, et al. Among authors: mirabel x. Radiother Oncol. 2018 Dec;129(3):463-470. doi: 10.1016/j.radonc.2018.08.008. Epub 2018 Aug 29. Radiother Oncol. 2018. PMID: 30172453 Clinical Trial.
Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).
Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V, Cowen D, Lepage C, Aparicio T; for FFCD investigators/Collaborators. Vendrely V, et al. Among authors: mirabel x. Radiother Oncol. 2019 Nov;140:84-89. doi: 10.1016/j.radonc.2019.05.018. Epub 2019 Jun 8. Radiother Oncol. 2019. PMID: 31185328 Clinical Trial.
Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer.
Vaugier L, Mirabel X, Martel-Lafay I, Racadot S, Carrie C, Vendrely V, Mahé MA, Senellart H, Raoul JL, Campion L, Rio E. Vaugier L, et al. Among authors: mirabel x. Cancers (Basel). 2021 Jan 11;13(2):248. doi: 10.3390/cancers13020248. Cancers (Basel). 2021. PMID: 33440832 Free PMC article.
Radiotherapy for cancers of the oesophagus, cardia and stomach.
Créhange G, Modesto A, Vendrely V, Quéro L, Mirabel X, Rétif P, Huguet F. Créhange G, et al. Among authors: mirabel x. Cancer Radiother. 2022 Feb-Apr;26(1-2):250-258. doi: 10.1016/j.canrad.2021.11.022. Epub 2021 Dec 23. Cancer Radiother. 2022. PMID: 34955417
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Vendrely V, Ronchin P, Minsat M, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Darut-Jouve A, de la Fouchardière C, Giraud N, Breysacher G, Argo-Leignel D, Thimonnier E, Magné N, Abdelghani MB, Lepage C, Aparicio T; for FFCD investigators/Collaborators. Vendrely V, et al. Among authors: mirabel x. Radiother Oncol. 2023 Sep;186:109742. doi: 10.1016/j.radonc.2023.109742. Epub 2023 Jun 12. Radiother Oncol. 2023. PMID: 37315583 Free article. Clinical Trial.
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
Modesto A, Tougeron D, Tremolières P, Ronchin P, Jouve AD, Leignel DA, Vendrely V, Riou O, Martin-Babau J, Le Sourd S, Mirabel X, Leroy T, Huguet F, Montaigne L, Baumgaertner I, Deslandres M, Moyal E, Seva C, Selves J, Otal P, Pezzella V, Guimbaud R, Filleron T, Quéro L. Modesto A, et al. Among authors: mirabel x. BMC Cancer. 2023 Oct 12;23(1):966. doi: 10.1186/s12885-023-11227-0. BMC Cancer. 2023. PMID: 37828434 Free PMC article.
148 results